We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Poseida Licenses Janssen’s Centyrins to Develop CAR Therapies

News   Aug 12, 2015

 
Poseida Licenses Janssen’s Centyrins to Develop CAR Therapies
 
 
 

RELATED ARTICLES

T Cell Study Uncovers New Hurdle for Developing Immunotherapies

News

There's an unexpected challenge to be overcome - T cell receptors can be more cross-reactive than previously thought.

READ MORE

Gout Get Outta Here

News

Researchers found a significant reduction in risk of gout attacks among patients who received the drug (canakinumab) that targets a key inflammatory molecule, suggesting a new target for therapeutic strategies to prevent gout attacks.

READ MORE

Cells Make Trade-offs in Fight Against Rhinovirus Infection

News

Mechanistic link between environmental exposures and susceptibility to the common cold revealed.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE